Display options
Cite
Huang YJ, Huang TW, Chao TY, et al. Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. Oncotarget. 2017;8(44):78144-78152doi: 10.18632/oncotarget.17839.
Huang, Y. J., Huang, T. W., Chao, T. Y., Sun, Y. S., Chen, S. J., Chu, D. M., Chen, W. L., & Wu, L. W. (2017). Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. Oncotarget, 8(44), 78144-78152. https://doi.org/10.18632/oncotarget.17839
Huang, Yi-Jhih, et al. "Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome." Oncotarget vol. 8,44 (2017): 78144-78152. doi: https://doi.org/10.18632/oncotarget.17839
Huang YJ, Huang TW, Chao TY, Sun YS, Chen SJ, Chu DM, Chen WL, Wu LW. Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. Oncotarget. 2017 May 12;8(44):78144-78152. doi: 10.18632/oncotarget.17839. eCollection 2017 Sep 29. PMID: 29100456; PMCID: PMC5652845.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 May 12;8(44):78144-78152. doi: 10.18632/oncotarget.17839. eCollection 2017 Sep 29.

Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome.

Oncotarget

Yi-Jhih Huang, Tsai-Wang Huang, Tsu-Yi Chao, Yu-Shan Sun, Shyi-Jou Chen, Der-Ming Chu, Wei-Liang Chen, Li-Wei Wu

Affiliations

  1. Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C).
  2. Division of Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C).
  3. Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, Republic of China (R.O.C).
  4. Division of Family Medicine, Tri-Service General Hospital Penghu Branch, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C).
  5. Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C).
  6. Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China (R.O.C).
  7. Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China (R.O.C).
  8. Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C).

PMID: 29100456 PMCID: PMC5652845 DOI: 10.18632/oncotarget.17839

Abstract

BACKGROUND: Tartrate-resistant phosphatase isoform 5a is expressed in tumor-associated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6.

METHODS: One hundred healthy volunteers were randomly selected, and cut-off points for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome.

RESULTS: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of >5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95% confidence interval, 0.618-0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012).

CONCLUSIONS: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-off level of 5.8 μg/L.

Keywords: metabolic syndrome; tartrate-resistant acid phosphatase

Conflict of interest statement

CONFLICTS OF INTEREST All authors declare that they have no financial or non-financial conflicts of interest.

References

  1. Clin Nephrol. 2009 Apr;71(4):387-96 - PubMed
  2. Curr Atheroscler Rep. 2010 Mar;12(2):110-8 - PubMed
  3. Medicine (Baltimore). 2015 Dec;94(48):e2165 - PubMed
  4. Am J Med. 2014 Dec;127(12 ):1242.e1-10 - PubMed
  5. Clin Chim Acta. 2011 May 12;412(11-12):963-9 - PubMed
  6. Diabetes. 2004 Jul;53(7):1773-81 - PubMed
  7. Circulation. 1995 May 1;91(9):2488-96 - PubMed
  8. Circ J. 2011;75(12):2739-48 - PubMed
  9. Circulation. 2002 Dec 3;106(23):2908-12 - PubMed
  10. Circ J. 2008 Dec;72(12):2046-50 - PubMed
  11. Clin Chim Acta. 2005 Sep;359(1-2):132-40 - PubMed
  12. J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32 - PubMed
  13. Clin Lab. 2006;52(9-10):499-509 - PubMed
  14. Metabolism. 2014 Oct;63(10):1265-71 - PubMed
  15. Anticancer Res. 2003 May-Jun;23 (3C):2783-8 - PubMed
  16. Clin Chem Lab Med. 2016 Oct 1;54(10 ):1579-87 - PubMed
  17. J BUON. 2015 Jan-Feb;20(1):325-31 - PubMed
  18. Eur J Clin Nutr. 2006 Jun;60(6):802-9 - PubMed
  19. BMC Cardiovasc Disord. 2014 Dec 19;14:196 - PubMed
  20. Clin Med Insights Cardiol. 2015 Feb 02;8(Suppl 3):23-33 - PubMed
  21. J Intern Med. 2012 Nov;272(5):484-91 - PubMed
  22. Clin Chem. 2001 Jan;47(1):74-80 - PubMed
  23. J Cardiometab Syndr. 2007 Spring;2(2):119-23 - PubMed
  24. Circulation. 2013 Jan 15;127(2):180-7 - PubMed
  25. Diabetes Obes Metab. 2012 Jul;14(7):616-25 - PubMed
  26. Expert Rev Mol Diagn. 2007 Sep;7(5):511-7 - PubMed
  27. J Clin Endocrinol Metab. 2002 May;87(5):2084-9 - PubMed
  28. Popul Health Metr. 2015 Mar 14;13:7 - PubMed
  29. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  30. Biochem Biophys Res Commun. 2003 Aug 22;308(2):320-4 - PubMed
  31. Metabolism. 2010 Jan;59(1):144-51 - PubMed
  32. J Am Coll Cardiol. 2007 Jan 30;49(4):403-14 - PubMed
  33. Clin Chim Acta. 2016 Jan 30;453:197-202 - PubMed
  34. J Formos Med Assoc. 2014 Jun;113(6):364-70 - PubMed
  35. Nutr Rev. 2013 Mar;71(3):168-79 - PubMed
  36. J Bone Miner Res. 2008 Aug;23 (8):1287-95 - PubMed
  37. Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:20-3 - PubMed
  38. Am J Clin Pathol. 2007 Apr;127(4):556-66 - PubMed

Publication Types